Introduction {#Sec1}
============

Urothelium is the epithelium that covers the urinary tract from renal pelvis to urethra. Human urothelial cancer may occur at any position in the urinary tract, yet with a higher frequency of existence in the urinary bladder. Urinary bladder cancer (UBC) is the second most commonly diagnosed genitourinary malignancy in the United States. It is estimated that 76,690 new cases as well as 16,390 deaths will occur in 2016 \[[@CR1]\]. Amid various histological types, transitional cell carcinoma accounts for most of the cases \[[@CR2], [@CR3]\]. Approximately 70% of the non-muscle invasive transitional cell carcinoma will relapse within 5 years after the first standard transurethral resection of the bladder tumor (TURBT) \[[@CR4]\]. Therefore, it demands intensive surveillance procedures, including long-term periodical cystoscopy screening, adjuvant intravesical chemotherapy and immunotherapy, which makes the disease one of the most expensive and suffering cancers worldwide \[[@CR5]\]. During the past decades, significant progresses have been made in unveiling the mechanisms associated with cancer initiation, development and metastasis. Potential culprits include the deletion in chromosome 9 \[[@CR6]--[@CR8]\], point mutations of the fibroblast growth factor receptor-3 (FGFR3) \[[@CR9], [@CR10]\] and alterations in tumor suppressor gene TP53 and RB1 \[[@CR11], [@CR12]\]. However, ascribed to the repercussion of a 'two-hit' or even multiple hits based on the Knudson hypothesis \[[@CR13]\], the bewildering story of cancer is far more complicated than we thought. Therefore, when the recent genome wide association studies (GWAS) revealed one of the solute carrier family gene, SLC14A1, is related to the carcinogenesis of UBC \[[@CR14]--[@CR17]\], it seems a new piece has just been added to the puzzle.

SLC14A1 gene and UT-B protein {#Sec2}
-----------------------------

Human solute carrier family 14 member 1 (SLC14A1) gene contains approximately 30 kb nucleotides, and is located on chromosome 18q12.1-21.1 \[[@CR18]\]. SLC14A1 encodes type-B urea transporter (UT-B), which resides in tandem with another urea transporter, UT-A, coded by SLC14A2 \[[@CR19]\]. Urea transporter facilitates the rapid and passive cross-membrane movement of urea \[[@CR19], [@CR20]\]. Moreover, human UT-B (hUT-B) also serves as the determinant antigen of Kidd blood group on erythrocytes \[[@CR19], [@CR21]\]. The coding sequence of SLC14A1 consists of 11 exons \[[@CR18]\]. So far, there have been two documented hUT-B isoforms, namely hUT-B1 and hUT-B2. hUT-B1 was first cloned from human bone marrow and shares 62.4% identity with the rabbit UT-A2 \[[@CR22]\]. The coding sequence of hUT-B1 initiates from exon 4 and ends at exon 11, comprising 1170 nucleotides that encode a 389aa protein. It has been verified that hUT-B1 transcript exists in multiple tissues including brain, heart, lung, kidney, bladder, and prostate \[[@CR23]--[@CR27]\]. hUT-B2, however, was first identified from bovine rumen and designated as bovine UT-B2 (bUT-B2), with an additional 55-amino acid encoded by exon 3 splicing into the N-terminal of the UT-B1 sequence \[[@CR28]\]. At first, hUT-B2 mRNA has only been identified in caudate nucleus (Genbank NM_001146037) \[[@CR29]\]. However, recently, hUT-B2 mRNA was discovered in the human urothelium \[[@CR25]\] (Table [1](#Tab1){ref-type="table"}).Table 1Properties of UT-B1 and UT-B2Human UT-B1Human UT-B2Coding geneSLC14A1 (Exon 4--11)SLC14A1 (Exon 3--11)Amino acids (nucleotides)389AA (1170 bp)445AA (1338 bp)Glycosylation siteAsn^211^Asn^211^Initial isolationHuman bone marrow \[[@CR22]\]Bovine Rumen \[[@CR28]\]Tissue distributionBrain, heart, lung, intestine, erythrocyte, kidney, bladder, prostate, testis, etc. \[[@CR23]--[@CR27]\]Caudate nucleus (Genbank NM_001146037) \[[@CR29]\], Bladder \[[@CR25]\]

The hUT-B protein, with both intracellular amino and carboxy termini, contains ten transmembrane spanning domains that are integrated into two internal hydrophobic repeats connected by a glycosylated extracellular loop (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR22], [@CR30]\]. Initially, there were two predicted N-glycosylation sites in the hUT-B protein when it was first cloned, Asn^211^ and Asn^291^ \[[@CR22]\]. However, the site Asn^291^ was later proved to be unrelated with glycosylation, yet its mutation as observed in Finns did affect the transport activity and membrane expression level \[[@CR31]\]. Therefore, Asn^211^, whose N-glycan chain also carries the ABO blood group antigens, is the only glycosylation site in hUT-B protein \[[@CR31]\]. But the mutation of Asn^211^ neither affects the protein expression level nor its transport activity, as observed on Xenopus oocytes \[[@CR32]\]. Another feature of hUT-B is that the protein does not conserve the potential protein kinase A (PKA) or protein kinase C (PKC) phosphorylation site as in UT-A2 \[[@CR22]\], whereas 7 cysteine residues of UT-B are aligned at equivalent positions of UT-A2. Another 2 cysteine residues, Cys^25^ and Cys^30^, together are essential for the plasma membrane addressing, according to a mutagenesis and functional study in Xenopus oocytes \[[@CR32]\].Fig. 1Protein structure of UT-B1 and UT-B2. Human UT-B protein contains 10 transmembrane spanning domains that are integrated into two internal hydrophobic repeats connected by a glycosylated extracellular loop, whose both amino and carboxy termini are intracellular. Asn^211^ is the only glycosylation site in human UT-B protein. The coding sequence of UT-B1 initiates from exon 4 and ends at exon 11, encoding a 389aa protein. UT-B2 has an additional 55-amino acid encoded by exon 3 splicing into the N-terminal of the UT-B1 sequence. Based on the structure theory of dvUT, urea transporter functions in the form of a homotrimer. Each promoter contains two homologous halves of the protein that has a cleft in the center. At the entrance, the parallel aromatic side chain of phenylalanine on each side forms a slot-like shape that enables only the planar urea molecule to enter

When analyzed by Western blot, the glycosylated hUT-B demonstrates a 46--60 kDa smear band in erythrocytes \[[@CR33]\] and a 41--54 kDa band in the kidney \[[@CR23]\], both of which can be deglycosylated with peptide-*N*-glycosidase F (PNGase F) and reduced to a 32 kDa core protein \[[@CR23]\]. Recently, a hUT-B specific signal has been detected in human bladder, which presents as a 40--45 kDa smear band that reduces to 30 kDa when deglycosylated with PNGase F \[[@CR25]\]. Therefore, this human bladder specific UT-B is similar with that has been identified in rodents. The glycosylated urothelium UT-B is approximately 41--54 kDa in mice \[[@CR34]\] and 35--56 kDa in rats \[[@CR35]\], whereas the deglycosylated forms of UT-B are 29 and 32 kDa in mice and rats, respectively \[[@CR34], [@CR35]\]. Nevertheless, whether it is hUT-B1 or hUT-B2 that is expressed on urothelium remains a mystery, since the mRNA of both isoforms has been located in the urothelial cells. Additionally, the antibodies used in the previous researches was designed for the hUT-B C terminus, which are incapable of identifying hUT-B1 and hUT-B2 that are distinguished in the N terminus where the truncation is a part of normal physiological regulation \[[@CR25], [@CR36]\].

In 2009, the crystal structure of a UT homologue from the bacterium *Desulfovibrio vulgaris* (dvUT) was revealed by X-ray crystallography, which offered us a better understanding on how urea transporter works (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR37]\]. The dvUT is a homotrimer. Each promoter contains two homologous halves of the protein that has a cleft in the center. At the entrance, the parallel aromatic side chain of phenylalanine on each side forms a slot-like shape that enables only the planar urea molecule to enter \[[@CR38], [@CR39]\]. Inside the cleft, three linearly lined oxygen atoms constitute the bilateral oxygen ladders that continuously interact with the urea molecules via hydrogen-binding sites \[[@CR37], [@CR38]\]. Thus, urea molecules exhibit a stepwise movement while crossing the transporter.

Urea is a highly polarized molecule. As stated in most text books, it is freely permeable across cell membranes while the process is extremely slow \[[@CR40]\]. Considering the transient time in which urine passes the collecting ducts of the kidney, this passive diffusion process may not be efficient enough to set up the intrarenal osmotic gradient solely and rapidly \[[@CR20]\]. It has been observed in UT-B knock-out mice that urine urea concentration is decreased while urine output is increased \[[@CR41], [@CR42]\]. Actually, different types of urea transporters are expressed along the renal tubules and the vasa recta. A high urea concentration is constituted in the inner medulla collecting duct (IMCD) when urine flows through the collecting duct and water is absorbed by aquaporins. Therein, urea is reabsorbed by a vasopressin-regulated process via two types of urea transporters---UT-A1 and UT-A3 \[[@CR43], [@CR44]\]. The reabsorbed urea enters the ascending vasa recta (AVR) through micropores on the endothelium, and is transferred to the descending vasa recta (DVR) via UT-B subsequently \[[@CR45], [@CR46]\]. This process forms a countercurrent exchange and helps to preserve the urea concentration gradient in the inner medulla.

In extra-renal tissues, UT-B is believed to prevent the intracellular urea intoxication, since relevant physiology studies in UT-B null mice have observed depression-like behavior and premature of male reproductive system \[[@CR24], [@CR47]\]. As a urine reservoir, the bladder is constantly exposed to the high concentration of urea, which is 20--100 times higher than that of the blood \[[@CR48]\]. Notably, UT-B exists throughout the layers of the urothelium except for the apical membrane of the umbrella cells \[[@CR25]\]. Additionally, it has been suggested that during the process of urine replenishing and voiding, urea may enter the apical urothelial cells via the endocytic trafficking pathway \[[@CR49]\]. Therefore, as observed in the urothelial cells of UT-B null mice, the cell cycle delay, apoptosis, and DNA damage caused by oxidative stress can be explained \[[@CR50]\], since high urea concentration may cause the damage of DNA \[[@CR51]\] and the disruption of the hydrophobic bonds within the protein \[[@CR52]\]. Considering this, the abundant existence of UT-B on the bladder urothelium may imply that the potential protective role of this urea transporter.

Molecular pathogenesis of bladder cancer {#Sec3}
----------------------------------------

Urinary bladder cancer (UBC) is derived from the uroepithelium that covers the urinary tract from the renal pelvis to urethra. The most commonly diagnosed type of UBC is transitional cell carcinoma, which is histologically distinct from other types of UBC such as squamous cell carcinoma (related with schistosomiasis or chronic bladder irritation \[[@CR53]\]) and adenocarcinoma (metastasized from prostate or colon \[[@CR54]\]). Generally, UBC can be classified by their clinical behavior and the extent of cancer malignancy: non-invasive carcinoma in which cancer confines within the basement membrane (flat, papillary or inverted) and invasive UBC \[[@CR55]\].

Papillary carcinoma (pTa UBC) arises from hyper-proliferation of the urothelium and leads to the urothelium to fold into a polyp that protrudes into the bladder. Except for papillary urothelial neoplasm of low malignant potential (PUNLMP), either low grade or high grade pTa UBC has a high tendency of recurrence \[[@CR55]\]. The most prevalent genetic alterations reported in papillary carcinoma includes the deletions of chromosome 9, point mutations in fibroblast growth factor receptor 3 (FGFR3) and alpha catalytic subunit of phosphatidylinositol 3-kinase (PIK3CA) \[[@CR7], [@CR56]\] (Table [2](#Tab2){ref-type="table"}).Table 2Well-established molecular pathways in UBCGeneAlterations in UBCFGFR3 (\~70%) \[[@CR9]\]Somatic mutation induced dimerization and auto-activation; wild-type overexpression \[[@CR9], [@CR10], [@CR59], [@CR60]\]Chromosome 9 (\~60%) \[[@CR6], [@CR8]\] CDKN2A/ARF(9p21)Deletion and methylation \[[@CR67], [@CR68]\] PTC(9q22)Deletion \[[@CR69], [@CR70]\] DBC1(9q33)Deletion and methylation of CpG island \[[@CR71]--[@CR73]\] TSC1(9q34)Loss of heterozygosity \[[@CR74]\]PI3K (\~30%, early event) \[[@CR77]\]PI3K/Akt pathway activation \[[@CR76], [@CR77]\]P53P53 nucleus accumulation \[[@CR80]\]P21^WAF^Loss of expression \[[@CR83]\]

FGFR3, member of the receptor tyrosine kinases family, regulates cell proliferation, differentiation and migration. The common structure of FGFR3 comprises an extracellular domain which includes three immunoglobulin (Ig) domains, a hydrophobic transmembrane region and an intracellular tyrosine kinase domain \[[@CR57]\]. In UBC, two FGFR3-involved mechanisms may account for the tumor genesis \[[@CR9], [@CR10], [@CR58]\]: first, the somatic point mutation within the FGFR3 creates a cysteine residue in the extracellular region, and gives rise to the receptor dimerization via the intermolecular disulphide bond formation followed by the ligand-independent receptor activation \[[@CR59], [@CR60]\]; Second, the overexpression of a wild-type receptor, which is more frequently observed in higher grade tumors. The former one is constantly associated with the low grade tumors. As observed in clinical cases, frequently mutations of FGFR3 in UBC are S249C (66.6%) and Y375C (15.1%), in exons 7 and 10, respectively \[[@CR61], [@CR62]\].

Deemed as one of the primary target in the carcinogenesis of UBC, chromosome 9 alterations are demonstrated in more than half of the tumors considering all grades and stages \[[@CR6]--[@CR8]\]. In previous studies, four main regions of gene deletion on chromosome 9 have been identified. On 9p21, it harbors the CDKN2A/ARF tumor suppressor gene that encodes two cell cycle regulatory proteins: cyclin-dependent kinase 2A (CDKN2A) and ARF. CDKN2A (inhibitor of CDK4) interacts with CDK4/6-cyclin D complex, maintaining the retinoblastoma (Rb) protein in its hypophosphorylated growth-suppressive form \[[@CR63], [@CR64]\]. The ARF, however, interacts with murine double minute 2 (MDM2), thereby inhibiting the degradation of p53 and holding the cell cycle in G1/S regulation point \[[@CR65], [@CR66]\]. Deletion and methylation of the CDKN2A gene inactivate both pathways, leading to an uncontrolled cell proliferation, which occurs primarily in superficial bladder tumors and is related to poor prognosis \[[@CR67], [@CR68]\]. On 9q22, a marker located in the first intron of the PATCHED (PTC) gene, a human ortholog of the drosophila PATCHED gene, shows the highest percentage of deletion in superficial UBC \[[@CR69]\]. In an animal research, BBN (*N*-butyl-*N*-(4-hydroxybutyl) nitrosamine) induced bladder preneoplastic and neoplastic changes were observed significantly earlier in the PTC^+/−^ mice comparing to wild-type, suggesting that the PTC might act as a tumor suppressor in UBC \[[@CR70]\]. In addition, within the DBC1 (deleted in bladder cancer 1) gene on 9q33, occasional homozygous deletion and methylation in CpG island have been reported in several studies \[[@CR71]--[@CR73]\]. Another gene that shows loss of heterozygosity in more than 50% of the transitional cell carcinomas is the tuberous sclerosis complex 1 (TSC1) on 9q34. The missense mutations of TSC1 were identified in 14.5% of the tumors, which causes the disfunction of TSC1 by aberrant splicing or reduced protein stability \[[@CR74]\].

Phosphoinositide-3 kinase (PI3K) catalytic unit p110 alpha (PI3KCA) interacts with the Ras protein in a GTP-dependent manner, leading to the activation of PI3K/protein kinase B (Akt) pathway \[[@CR75]\]. The PI3K/Akt signaling pathway, which demonstrates a prevalent activation in the entire spectrum of UBC, is considered to play a major role in carcinogenesis. In T1 and T2 UBC, high frequency of PI3KCA gene alteration has been observed. However, the presence of PI3KCA gene alteration is significantly associated with reduced recurrence of non-muscle invasive UBC \[[@CR76], [@CR77]\].

Invasive UBC, which generates from the flat dysplasia that leads to the CIS, comprises the tumors invading through the lamina propria into the muscularis of, or beyond, the bladder wall. Generally speaking, invasive bladder tumors frequently show alterations in p53 and Rb pathways \[[@CR12], [@CR78]\]. p53 is the most commonly mutated genes in human cancer, including UBC. Missense point mutations as well as the loss of a single TP53 gene allele lead to the p53 protein resistance to normal regulatory degradation by ubiquitin pathway and accumulation in the nucleus \[[@CR79]\]. It has been observed that the accumulation of inefficient p53 in the nucleus is correlated with a worse pathological outcome, increased risk of recurrence and decreased overall survival rate \[[@CR80]\]. p21^WAF1^ is an important downstream target of the p53 pathway. p21^WAF1^ acts as a cyclin-dependent kinase and regulates the G1-S-phase transition in the cell cycle \[[@CR81], [@CR82]\]. Loss of p21^WAF1^ expression is an independent predictor of UBC progression. Maintenance of its expression tends to counteract the deleterious effects of p53 alterations on UBC progression \[[@CR83]\]. Meanwhile, alterations in both Rb and p53 pathway have been observed to act in a cooperative manner to promote cancer progression \[[@CR11]\].

SLC14A1 and UBC, a complicated story {#Sec4}
------------------------------------

In 2011, Frullanti identified the down-regulated expression of SLC14A1 in lung adenocarcinoma (ADCA) specimens and A549 (ADCA) cell lines. Meanwhile, they also discovered that transfecting the NCI-H520 (lung squamous cell carcinoma) cell line with the SLC14A1 gene significantly inhibited the colony formation \[[@CR27]\]. In Markku's research, SLC14A1 gene was found down-regulated by 2.88-fold in the malignant prostate cancer tissues compared with the benign ones using a genechip assay. Castration, however, elevated SLC14A1 expression by 3.05-fold, indicating that the expression of SLC14A1 gene in prostate could be regulated by androgen \[[@CR26]\]. Meanwhile coincidentally, the expression level of SLC14A1 is also indentified to be suppressed in UBC, which, more importantly, is inversely proportional with the clinical grade and stage \[[@CR84]\].

So far, GWAS researches have revealed several suspicious SNPs (single nucleotide polymorphism) within the SLC14A1 gene that are strongly associated with bladder cancer, such as rs1058396, rs2298720, rs11877062 and rs17674580 \[[@CR14]--[@CR17]\]. Accordingly, the G allele at nucleotide 838 of rs1058396 which encodes Asp280 defining Jk(A) in the Kidd blood system turns out to be a risk allele, and the transition from G to A (Asn280), which encodes Jk(B), tends to be a protective allele \[[@CR14]\]. Another protective allele indicated by GWAS is rs2298720 \[[@CR14]\]. The non-synonymous variant rs2298720 (Glu44Lys) defines a weaker Jk(A) antigen-Jk(A)W. Compared to its wild type, the Jk(A)W UT-B has a Val-Gly triplicate after Pro227 and demonstrates a weaker signal when transfected and expressed on the membrane of the Xenopus oocyte \[[@CR85]\]. However, even though the in vitro experiment has demonstrated that the urea transport facilitated by JK(A)W is less effective than JK(A) \[[@CR85]\], there is no direct evidence currently indicating the differences in renal function among the people bearing JK(A), JK(B) and JK(A)W \[[@CR14]\]. In 2013, Koutros et al. discovered that people bearing another risk SLC14A1 allele, rs10775480, manifest a decreased urine specific gravity, which was independent of urination frequency and urine output \[[@CR86]\]. Therefore, the urinary bladder, or human urothelium to be specific, could play an important role in the urinary solute regulation, just as previously described by Dr. Apodaca \[[@CR49]\], and such regulatory malfunction could be the culprit for the development of UBC.

In the UT-B knock-out mice, the 'urea scavenger' deficiency has caused severe apoptosis and DNA damage in the urothelial cells where the urea concentration is nine times higher than that of the wild type \[[@CR50]\]. This devastating phenomenon possibly caused by urea accumulation coincides with a previous study, in which high urea concentration had caused cell cycle delay in G2/M and G0/G1 phase as well as the apoptotic cell death \[[@CR51]\]. Based on the chemical reaction of Wöhler synthesis discovered in 1828, urea can spontaneously transform into cyanate and ammonia at body temperature and pH \[[@CR87]\]. Cyanate then converts free amino acids into carbamoyl amino acids, which can in turn interfere with protein synthesis \[[@CR88]\]. Additionally, urea can also destabilize protein by decreasing the hydrophobic effect and directly binding with the amide groups through hydrogen bond \[[@CR52]\]. In addition, plasma urea concentration of UBC patients was observed to be significantly elevated \[[@CR89]\]. Therefore, the suppressed expression of hUT-B in the background of UBC could possibly lead to the urea accumulation within the urothelial cells, which subsequently induces the generation of cytotoxic reagents, severe protein and DNA damage, and the eventual apoptosis. Intriguingly, cancer development in which proliferation is frequently involved is divergent from programmed cell death in many ways. However, it has been reported that during the process of apoptosis, receptors such as FAS and TNF-related apoptosis-inducing ligand receptor (TRAILR) may present non-apoptotic functions, including proliferation and invasion, which can possibly induce the development of cancer \[[@CR90], [@CR91]\]. Thus, in the future researches, the function of TRAILR in UT-B knock-out models should be investigated.

Another effect of urea accumulation inside the urothelium is the alteration of [l]{.smallcaps}-arginine metabolism, which increases the intracellular level of inducible NO synthase (iNOS) \[[@CR50]\]. As a downstream target, hypoxia-inducible factor-1 (HIF-1) is stabilized by the high concentration of nitric oxide (NO) synthesized via iNOS catalyzing \[[@CR92], [@CR93]\]. Consequently, the sequestration of urea within the urothelial cells stabilizes HIF-1, a negative regulator of argininosuccinate synthetase 1 (ASS-1) \[[@CR94]\]. The gene encodes ASS-1 is localized on chromosome 9q34. It has been reported that the ASS-1 may act as a cancer suppressor, and was lost in approximately 40% of the UBC, primarily caused by the transcriptional suppression induced by HIF-1 or the well-known chromosome 9 deletion \[[@CR8], [@CR95]\]. Meanwhile, HIF-1 also competes with p53 for p300, a transcriptional activator \[[@CR96]\]. In concomitance with the inability of p53 caused by genetic mutation, the HIF-1 becomes the dominantly activated by p300 \[[@CR97]\], and is also identified to enhance the expression level of FGFR3 in non-muscle invasive UBC \[[@CR98]\]. Therefore, it seems that the urea accumulation induced by hUT-B dysfunction in the urothelium may trigger intracellular metabolic disorders that could interact with canonical UBC pathways (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Illustration of the relationship between SLC14A1 and UBC. UT-B may act as a tumor suppressor that is somehow down-regulated by suppressive factors, inducing intracellular urea accumulation. In addition to the elevated plasma urea level, intracellular urea overload can cause protein/DNA damage and trigger and apoptosis. Subsequently, the apoptosis may induce the activation of TRAILR and the initiation of cancer. On the other hand, urea accumulation could alter the intracellular arginine metabolism, which activates HIF-1 via NO. HIF-1 may interact with canonical UBC pathways including FGFR3, chromosome 9 and p53. Notably, the DVR UT-B expression in the background of UBC probably needs more attention in the future research, since it serves to regulate urine volume and frequency, which can be the causes for urothelium neoplasms

Hence, it could be postulated that UT-B might act as a tumor suppressor that is somehow down-regulated, inducing intracellular urea accumulation which in turn causes DNA damage and triggering the initiation of cancer via multiple pathways. However, whether such down-regulation of UT-B is an universal event that could impair its capacity in orchestrating urine volume and frequency remains unclear. It has been reported that urination frequency and volume could be the potential causes for urothelium neoplasms \[[@CR99], [@CR100]\]. Therefore, further research should consider the urothelial UT-B and the DVR UT-B wholly when evaluating the association between SLC14A1 gene and UBC (Fig. [2](#Fig2){ref-type="fig"}).

Conclusion {#Sec5}
==========

The alternative expression of SLC14A1 in human UBC has been observed in several studies, including large population-based GWAS researches. Based on the literatures in this review, we conclude that the impaired expression of UT-B in human urothelial cells could lead to urea intracellular accumulation and subsequent metabolic disorders. Accordingly, we postulated that two potential downstream pathways could be involved in the carcinogenesis under such circumstances, including apoptosis-induced proliferation that activated by TRAILR, and NO triggered HIF-1 promoted oncogene expression and tumor suppressor gene down-regulation. However, more comprehensive investigations are needed to elucidate the underlying mechanisms that initially caused the repression of SLC14A1 in UBC, and to unveil the relationship between aberrant SLC14A1 expression and the carcinogenesis of UBC. Additionally, the cooperation of renal and extra-renal UT-B in the development of UBC should be considered as well, since urination frequency and volume may also play an important role. In sum, SLC14A1 and UT-B should be a novel and promising research target in the field of urothelial cancer.
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